

Anti-IL-5R α (Benralizumab), Humanized Antibody

07/20

CATALOG NO.: A2162-100 (100 μ g)

BACKGROUND DESCRIPTION: The research-grade biosimilar is a humanized IgG1 monoclonal antibody that selectively binds to isoleucine 61 amino acid residue in the domain 1 of IL-5R α . Binding of the antibody prevents the interaction of IL-5 with the receptor and heterodimerization of α and β c subunits, thus inhibiting IL-5 mediated signaling. Additionally, the antibody binds via its Fc constant region to the Fc γ RIIIa receptor located on the surface of NK cells and thus induces eosinophil apoptosis via the release of proapoptotic proteins such as granzyme B and perforins. The original drug received FDA approval in 2017 to treat severe eosinophilic asthma. The US FDA also granted orphan drug designation to this drug in 2019 for the treatment of eosinophilic esophagitis.

ALTERNATE NAMES: BIW-8405, MEDI-563, KHK4563, IL5R, CD125, CDw125, HSIL5R3

ANTIBODY TYPE: Monoclonal

CONCENTRATION: 1 mg/ml

HOST/ISOTYPE: Recombinant / IgG1, kappa

SOURCE: CHO cells

IMMUNOGEN: Human IL-5R α

CAS NUMBER: 1044511-01-4

MOLECULAR WEIGHT: 146 kDa

PURIFICATION: Protein A purified

FORM: Liquid

FORMULATION: In PBS, pH 7.5

SPECIES REACTIVITY: Human

STORAGE CONDITIONS: Store at -80°C

This information is only intended as a guide. The optimal dilutions must be determined by the user

RELATED PRODUCTS:

Anti-PD-L1 (Durvalumab), Human IgG1 Antibody (A2109)
 Anti- α 4 β 7 Integrin (Vedolizumab), Humanized Antibody (A2140)
 Anti-IgE (Omalizumab), Humanized Antibody (A2145)
 Anti-IL5 (Mepolizumab), Humanized Antibody (A2158)
 Anti-IL-4R α (Dupilumab), Human IgG4 Antibody (A2148)

FOR RESEARCH USE ONLY! Not to be used on humans.